Fmoc-Thr-OH | 73731-37-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苏氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-Thr-OH
• 英文别名: Fmoc-T-OH；(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-hydroxybutanoic acid
• CAS: 73731-37-0；130674-54-3；146306-75-4
• 化学式: C₁₉H₁₉NO₅
• 分子量: 341.364
• InChiKey: OYULCCKKLJPNPU-KLLZUTDZSA-N

物化性质

• 熔点：
  115°C (dec.)
• 比旋光度：
  -16 º (c=1%, DMF)
• 沸点：
  596.5±50.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险品运输编号：
  OTH
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  密封，在温室中保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-d-allo-thr-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-d-allo-thr-oh
CAS number: 130674-54-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C19H19NO5
Molecular weight: 341.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于生化试剂和多肽合成。

反应信息

• 作为反应物：
  描述：

  2,3,4,5-tetra-O-acetyl-D-glucopyranose 、 Fmoc-Thr-OH 在 吡啶 、 indium(III) bromide 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 Fmoc-L-Thr-(O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl])pentafluorophenyl ester
  参考文献：
  名称：

  malformin-A1、C、聚糖和苷元类似物的合成：靶向癌症治疗的潜在支架

  摘要：

  在降低化疗副作用的同时提高治疗效果仍然是癌症治疗合成设计的重要目标。为了与治疗发展的精神保持一致，并受到 Warburg 效应的启发，该效应增强了环肽天然产物三甲双胍家族的生物活性，特别是抗肿瘤活性，β利用精确的糖基化和液相肽合成设计和合成了二甲双胍 C 的葡萄糖苷。我们利用不同的供体和受体优化了几种糖基化程序。本研究的首要目标是确保通过 D-葡萄糖部分的偶联有针对性地递送糖-二甲双胍 C 类似物。通过葡萄糖转运蛋白 (GLUT) 选择性转运到肿瘤细胞中，然后在肿瘤微环境中水解，释放活性的 malformin C a 糖基类似物。此外，采用整体改进的策略进行了三甲双胍 C 的全合成，避免了不需要的副反应，从而增加了更容易纯化。我们还报告了一种改进的三甲双胍 A 1固相肽合成方案。

  DOI：

  10.1002/pep2.24260
• 作为产物：
  描述：

  氯甲酸-9-芴基甲酯 、 L-苏氨酸 生成 Fmoc-Thr-OH
  参考文献：
  名称：

  MALMER, MARCIA F.;SCHROEDER, LAUREN ALFRED, J. CHROMATOGR., 514,(1990) N, C. 227-239

  摘要：

  DOI：

文献信息

• Novel Ligands Lacking a Positive Charge for the δ- and μ-Opioid Receptors
  作者：Peter W. Schiller、Irena Berezowska、Thi M.-D. Nguyen、Ralf Schmidt、Carole Lemieux、Nga N. Chung、Margaret L. Falcone-Hindley、Wenqing Yao、Josephine Liu、Seiji Iwama、Amos B. Smith、Ralph Hirschmann

  DOI：10.1021/jm990461z

  日期：2000.2.1

  same libraries for ligands of the delta-opioid receptor, we identified four compounds (1-4) which represent a new class of delta-opioid antagonists, some of which were also NK-1 receptor antagonists. The most potent delta-opioid antagonist, c[-Pro-1-Nal-D-Trp-Tyr-Thr-Phe-] (2), showed a K(e) value of 128 nM in the mouse vas deferens assay and a delta-receptor binding affinity constant of 152 nM in the

  最近，我们报道了使用微型文库取代有效的生长抑素激动剂L-363,301（c [-Pro-Phe-D-Trp-Lys-Thr-Phe-]）的Lys（9）[生长抑素（SRIF）编号]以产生有效的神经激肽受体（NK-1）拮抗剂c [-Pro-Phe-D-Trp-pF-Phe-Thr-Phe-]。这种新的环状六肽不结合SRIF受体。因此，单个突变转化了L-363,301，一种具有约ca.10效力的SRIF激动剂。SRIF在实验动物中效力的2-8倍（24）在体外具有选择性IC-1（50）为2 nM的选择性NK-1受体拮抗剂。在针对δ阿片受体配体的相同文库的筛选过程中，我们鉴定了代表新一类δ阿片拮抗剂的四种化合物（1-4），其中一些也是NK-1受体拮抗剂。最有效的δ阿片类药物拮抗剂c [-Pro-1-Nal-D-Trp-Tyr-Thr-Phe-]（2），在小鼠输精管试验中显示的K（e）值为128 nM
• (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150175615A1

  公开（公告）日：2015-06-25

  A compound represented by formula (1) or pharmaceutically acceptable salt thereof: wherein R 1 is a C 1-6 alkyl group; R 2 and R 3 are the same or different from each other and each is a hydrogen atom or a C 1-6 alkyl group; X 2 , X 3 and X 4 are the same or different from each other and each is a hydrogen atom or a halogen atom; and X 5 is a hydrogen atom or —P(═O)(OH) 2 has a Wnt Pathway modulating activity.

  由以下化学式（1）表示的化合物或其药用可接受的盐：其中R1是C1-6烷基基团；R2和R3彼此相同或不同，每个都是氢原子或C1-6烷基基团；X2、X3和X4彼此相同或不同，每个都是氢原子或卤原子；X5是氢原子或—P(═O)(OH)2具有Wnt通路调节活性。
• PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVIC

  公开号：US20160039872A1

  公开（公告）日：2016-02-11

  The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected pho-phoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.

  该发明提供了可能用作抗癌治疗的新化合物。该发明的化合物通过波洛盒结构结合到波洛样激酶。在某些实施方式中，该发明的化合物是POM保护的肽衍生物。在结合了阳离子双烷基组氨酸残基和单个POM保护的磷酸化基团的情况下，得到的肽具有整体中性电荷。该发明的肽衍生物既具有良好的疗效又具有增强的生物利用度。该发明还提供了使用方法、组合物和相关试剂盒。此外，该发明提供了一种新的设计和/或合成磷酸化肽衍生物的方法，这些衍生物可用作治疗剂。
• Parallel solid phase synthesis of tetrasubstituted diethylenetriamines via selective amide alkylation and exhaustive reduction of N-acylated dipeptides
  作者：Adel Nefzi、John M. Ostresh、Richard A. Houghten

  DOI：10.1016/s0040-4020(98)01043-6

  日期：1999.1

  Polyamines are a rapidly developing area of vital importance to biomedical science. Selective N-alkylation followed by N-terminal acylation and the complete reduction of carbonyl amide bonds enables the preparation by parallel solid phase synthesis of a wide range of N1,N5,1,4-tetrasubstituted-1,5-diamino-3-azapentane derivatives.

  多胺是对生物医学至关重要的快速发展领域。选择性的N-烷基化，接着通过N-末端酰化和的羰酰胺键的完全降低使得能够通过宽范围的N个并行固相合成制备1，N 5，1,4-四取代-1,5-二氨基-3- -氮杂戊烷衍生物。
• Antiinfective Lipopeptides
  申请人：Alexander Christopher Dylan

  公开号：US20080051326A1

  公开（公告）日：2008-02-28

  The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脱氨肽类化合物。该发明还涉及这些化合物的药物组合物以及将这些化合物用作抗菌化合物的方法。该发明还涉及生产这些新型脱氨肽类化合物以及用于生产这些化合物的中间体的方法。